newswire, breaking biotechnology and pharma news

Monday, February 27, 2012

Biopharmaceutical Stock to Watch; Alimera Sciences (NASDAQ:ALIM) Gains over 35%

New York, New York – February 27, 2012 -, an investor research portal specializing in sector research including biotech and pharma stocks, issues a trading alert for Alimera Sciences, Inc. (NasdaqGM: ALIM), trading up at $2.3092, gaining 0.5992 or (35.04%) as of 1:22PM EST on over 800,000 shares.

The Company announced Friday that Dan Myers, president and chief executive officer, will present at the Citi 2012 Global Health Care Conference at 1:30 P.M. ET on Wednesday, February 29, 2012 at The Waldorf Astoria Hotel in New York City.

Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently Alimera is focused on diseases affecting the back of the eye, or retina. Its advanced product candidate, ILUVIEN, is an intravitreal insert containing fluocinolone acetonide (FAc), a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. ILUVIEN is in development for the treatment of DME, a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness.

About is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.

Sign up for the free investor news and stock alerts

Research biotech stocks at the Biotech stocks Directory:

Become an Member

Follow on Twitter!/Investorideas
Follow on Facebook

Disclaimer/ Disclosure : The is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info:
800-665-0411 - Source –

1 comment:

  1. Level 3 Data’sreal-time stock charting shows its patent pending Pressure Indicator to identify buy sell signalsfor real-time stock quotesand buying stocks online.stock market today